Dear colleague, This is an exciting time for us as a team – cemiplimab represents the first and only drug approved by both the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA) for the treatment of patients with advanced cutaneous squamous cell carcinoma (CSCC).
NEWSLETTER:
Cemiplimab Medical Training (Meeting 3)
20 November 2019 | Amsterdam
Dear colleague,
This is an exciting time for us as a team – cemiplimab represents the first and only drug approved by both the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA) for the treatment of patients with advanced cutaneous squamous cell carcinoma (CSCC). As cemiplimab begins to improve outcomes for patients with CSCC in the real-world setting, we must continue to ensure that we are prepared for conversations with healthcare professionals involved in the management of this debilitating condition.
I’m pleased to share with you a summary from our Cemiplimab Medical Training Meeting held in Amsterdam on 20 November 2019 – this was an important training day that I hope has provided you with information to support you now and in the upcoming months.
Overview of the management of CSCC, including the competitor landscape and possible new indications for cemiplimab
•
An introduction to basal cell carcinoma (BCC)
•
Publication update
Our packed training agenda included both internal data presentations and updates, as well as expert insights from the internationally renowned dermatologist Professor Nicole Basset-Seguin.
This newsletter summarises the key take-home messages from each session and your feedback from the day.
All of the slides from the Cemiplimab Medical Training Meeting are available on Cemiplimab Connections.
Some other key updates following the training meeting include:
